A comprehensive view of Viiv Healthcare Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva cabotegravir + rilpivirine compared to daily oral therapy in individuals with HIV who have adherence challenges

ViiV Healthcare reports positive findings from Phase 1 study of a new ultra-long acting cabotegravir formulation for HIV treatment, potentially enabling dosing intervals of at least four months; data support further development of CAB-ULA

ViiV Healthcare's long-acting injectable antiretroviral treatment for HIV, Cabenuva, shows superior efficacy in maintaining viral load suppression compared to daily oral therapy; results come from interim results from Phase 3 trial

ViiV Healthcare announces new blister packaging option now available in US for Dovato, a complete regimen to treat HIV-1 infection; blister pack supports treatment discretion and portability for some people living with HIV

China approves ViiV Healthcare's injectable HIV treatment consisting of Vocabria cabotegravir and Janssen's Rekambys rilpivirine; HIV affects over 1 million people in China

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count